Mölnlycke Health Care AB: CEO, Zlatko Rihter, announces resignation, Guillaume Joucla appointed interim CEO
Tue, Mar 24, 2026 Today, it was announced that Zlatko Rihter, CEO of Mölnlycke Health Care, has informed the Board of Directors of his decision to resign. Following his decision, Guillaume Joucla, Chief Financial Officer, has been appointed interim CEO of Mölnlycke Health Care. Mölnlycke’s Board has initiated the recruitment process for a permanent CEO.
“Zlatko has been instrumental in navigating Mölnlycke through an ever‑changing world while delivering above‑market growth. The company has made significant progress, with a relentless focus on customer centricity and geographic expansion,” says Mölnlycke’s Chair of the Board, Karl-Henrik Sundström.
“It has been a privilege to lead Mölnlycke for more than five years, a period of fantastic development and growth. The company is well positioned to continue its growth journey. I am proud of what we have achieved, and I want to sincerely thank all my colleagues for their hard work and strong commitment. I would also like to thank the Board for its support during my tenure,” says Zlatko Rihter.
“We are pleased to have Guillaume Joucla serve as interim CEO and lead the company forward, building on its key strengths. Guillaume has an excellent track record and extensive experience, having served almost 20 years with the company,” says Karl-Henrik Sundström.
Latest news
-
High burnout among operating room staff poses significant risk to patient safety—new review reveals
Gothenburg, Sweden. 17 September 2025. A new narrative review published in the current issue of Journal of Patient Safety, titled ’Putting Patients at Risk: The Effect of Health Care Provider Burnout on Patient Care in the Operating Room’ reveals alarmingly high levels of burnout among healthcare workers in operating rooms (ORs) and warns of the serious implications for staff well-being, care quality and ultimately patient safety.
-
Filippa Stenberg joins Mölnlycke Board of Directors
-
Mölnlycke awarded second consecutive EcoVadis Platinum medal for sustainability performance
Gothenburg, Sweden. 21 August 2025. Mölnlycke®, a world-leading MedTech company, has once again been recognised as a global sustainability leader, earning the prestigious EcoVadis Platinum medal for the second year in a row.
-
Mölnlycke Health Care expands investment in Tamer Mölnlycke Care joint venture
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.
-
Mölnlycke Health Care agrees to acquire leading wound cleansing manufacturer to consolidate its position as global leader in wound care
Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.
-
EUR bond issue and tender announcement
Mölnlycke intends to issue a new 10-year EUR bond and launches a tender offer for the outstanding EUR 500m bond due February 2025.
-
Mölnlycke signs a EUR 350 million revolving credit facility
On 28 April 2023, Mölnlycke entered into a new EUR 350 million multicurrency revolving credit facility. The facility has a tenor of five years with two one-year extension options and will be used as a backup for general corporate purposes. The facility is a refinancing of the existing and undrawn revolving credit facility signed in 2017.
-
In 2023 Mölnlycke was awarded a gold medal for Sustainability by EcoVadis
The world’s largest and most trusted provider of business sustainability ratings - EcoVadis, has awarded Mölnlycke a gold medal for our focus on sustainability. They have ranked us in the top 3% of companies worldwide.
-
Mölnlycke Health Care’s long-term target to reach net zero emissions validated by Science Based Targets initiative
Gothenburg, Sweden. 13 May, 2025. Mölnlycke’s long-term net zero greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi), following prior validation of the company’s near-term GHG emission reduction targets.